EPHB2 and rheumatoid arthritis: ROC analysis and AUC estimation showed that baseline levels of any of MSA4A, PDZK1IP1, and EPHB2 gene expression signature scores may discriminate between RA patients at Day 0, 6 months and 12 months follow-up as compared with healthy controls.